Enanta Pharmaceuticals (Enanta Pharmaceuticals) Valuation Rank

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Enanta Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

9EP:Germany

Address

500 Arsenal Street, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Executives

Terry Vance	director	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Scott T. Rottinghaus	officer: Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu	officer: Sr. VP, Business Dev.	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer	officer: Sr. VP, New Product Dev.	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or	officer: Chief Scientific Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly	director, officer: President and CEO	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner	director	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett	officer: Treasurer and CFO	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda	officer: Sr. VP & Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Yujiro S Hata	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta	director	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901